KANTAR HEALTH BLOG

kh_blog_hero_1600px
  • The Patient's Voice on More than 200 Health Conditions

    by Michael Fronstin  |  Oct 9, 2017
    Michael Fronstin highlights disparities in health spending, outcomes and quality of life across major health markets in a review of new data from the National Health and Wellness Survey.
  • Getting Inside the Patient – Part 2

    by Tim Irfan  |  Oct 6, 2017
    This blog explains how to achieve success in ethnographic research studies, allowing pharmaceutical companies to approach the patient in a new way that's both meaningful and helpful to the patient and worthwhile for companies.
  • Results from three phase III trials of could change treatment practice, should be considered strong enough to convince physicians and their patients to increase use of adjuvant treatment. As these trials differed in their patient populations and offered differing efficacy/toxicity profiles, potential utilization of Tafinlar (dabrafenib, Novartis) with or without Mekinist (trametinib, Novartis) as well as Opdivo (nivolumab, Bristol-Myers Squibb / Ono Pharmaceuticals) will be discussed. It may not be as simple as “offer BRAF/MEK inhibition to BRAF mutant patients."
  • In order to improve patient care we can no longer afford to view the patient in isolation, but instead must explore all influences on a disease to gain the deepest understanding of patient behaviors and the motivators behind them. This blog reviews how exploring the psyche of an individual provides an enhanced understanding of disease and how it impacts a patient from a human perspective.
  • The data from MONARCH 3 could extend the data from MONARCH 2, and if approved add the CDK4/6 inhibitor abemaciclib (Eli Lily) to several other approved agents that are being combined with hormone therapy for HR+, HER2- breast cancer. As the data from MONARCH 3 (as well as MONARCH 2) suggest a slightly different toxicity profile from either Ibrance (palbociclib, Pfizer) or Kisqali (Novartis), the future competitive landscape that could arise is discussed.